1FW2 logo

WuXi Biologics (Cayman) DB:1FW2 Stock Report

Last Price

€2.13

Market Cap

€8.9b

7D

5.2%

1Y

-32.9%

Updated

24 Dec, 2024

Data

Company Financials +

WuXi Biologics (Cayman) Inc.

DB:1FW2 Stock Report

Market Cap: €8.9b

1FW2 Stock Overview

An investment holding company, provides end-to-end solutions and services for biologics discovery, development, and manufacturing for biologics industry in the People’s Republic of China, North America, Europe, Singapore, Japan, South Korea, and Australia. More details

1FW2 fundamental analysis
Snowflake Score
Valuation4/6
Future Growth2/6
Past Performance2/6
Financial Health5/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

WuXi Biologics (Cayman) Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for WuXi Biologics (Cayman)
Historical stock prices
Current Share PriceHK$2.13
52 Week HighHK$3.61
52 Week LowHK$1.15
Beta0.60
1 Month Change20.57%
3 Month Change36.95%
1 Year Change-32.89%
3 Year Changen/a
5 Year Change-43.35%
Change since IPO99.44%

Recent News & Updates

Recent updates

Shareholder Returns

1FW2DE Life SciencesDE Market
7D5.2%-2.8%-2.0%
1Y-32.9%-5.6%6.8%

Return vs Industry: 1FW2 underperformed the German Life Sciences industry which returned -5.6% over the past year.

Return vs Market: 1FW2 underperformed the German Market which returned 6.8% over the past year.

Price Volatility

Is 1FW2's price volatile compared to industry and market?
1FW2 volatility
1FW2 Average Weekly Movement12.1%
Life Sciences Industry Average Movement7.1%
Market Average Movement4.9%
10% most volatile stocks in DE Market11.4%
10% least volatile stocks in DE Market2.4%

Stable Share Price: 1FW2's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: 1FW2's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
201412,435Chris Chenwww.wuxibiologics.com

WuXi Biologics (Cayman) Inc., an investment holding company, provides end-to-end solutions and services for biologics discovery, development, and manufacturing for biologics industry in the People’s Republic of China, North America, Europe, Singapore, Japan, South Korea, and Australia. It operates through two segments: Biologics and XDC. The company provides a suite of solutions for biologic discovery, from concept to IND, that seamlessly transits to CMC and downstream process development through its contract research, development, and manufacturing organization platforms, including WuXiBody, SDArBodY, T cell engager, Single B Cell Cloning Technology, WuXia, WuXiUP, WuXiUI, and WuXiHigh.

WuXi Biologics (Cayman) Inc. Fundamentals Summary

How do WuXi Biologics (Cayman)'s earnings and revenue compare to its market cap?
1FW2 fundamental statistics
Market cap€8.87b
Earnings (TTM)€347.04m
Revenue (TTM)€2.26b

25.6x

P/E Ratio

3.9x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
1FW2 income statement (TTM)
RevenueCN¥17.12b
Cost of RevenueCN¥10.50b
Gross ProfitCN¥6.62b
Other ExpensesCN¥3.99b
EarningsCN¥2.63b

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)0.64
Gross Margin38.66%
Net Profit Margin15.38%
Debt/Equity Ratio4.8%

How did 1FW2 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 02:25
End of Day Share Price 2024/12/23 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

WuXi Biologics (Cayman) Inc. is covered by 54 analysts. 25 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Linda LuBOCI Research Ltd.
Wai Chak YuenBOCI Research Ltd.
Bo LiBofA Global Research